Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Akums Drugs & Pharmaceuticals Ltd. Share Price
Day's Range
Day's Range
Low
₹509.15
High
₹527.40
Price Summary
| Previous Close | ₹521.35 |
|---|---|
| Day's Range | ₹509.15 - ₹527.40 |
| Open | ₹516.00 |
| 52 Week Range | ₹409.30 - ₹622.95 |
| Volume | 2,21,302 |
| Market Cap | ₹0.01 |
| Previous Close | ₹521.10 |
|---|---|
| Day's Range | ₹509.90 - ₹527.45 |
| Open | ₹516.90 |
| 52 Week Range | ₹410.10 - ₹620.00 |
| Volume | 8,656 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1,153.76 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.58 |
| Price/Earning (TTM) | 32.14 |
| TTM EPS (₹) | 16.21 |
| P/E Ratio | 21.49 |
| Book Value(₹) | 2.47 |
| PAT Margin (%) | 8.35 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 17.83 |
| Trade Value ( ₹ in Lacs) | 45.11 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.58 |
| Price/Earning (TTM) | 32.14 |
| TTM EPS (₹) | 16.21 |
| P/E Ratio | 21.49 |
| Book Value(₹) | 2.47 |
| PAT Margin (%) | 8.35 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 17.83 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 10555.47 | 41181.58 |
| Expenses | N/A | N/A |
| PBT | 751.36 | 3452.53 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1496.06 | 3437.77 |
About Akums Drugs & Pharmaceuticals Ltd.
| Founded | 2004 |
|---|---|
| Managing Director | Sanjeev Jain |
| NSE Symbol | AKUMS |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,53,750.23 | 1,891.15 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,82,116.76 | 6,856.20 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,51,313.88 | 4,474.05 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,19,400.22 | 8,313.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,225.36 | 1,401.65 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,10,037.00 | 1,319.00 | 1,148.40 - 1,148.40 |
| Max Healthcare Institute Ltd. | 1,06,234.43 | 1,091.55 | 903.00 - 903.00 |
| Lupin Ltd. | 1,04,489.83 | 2,287.25 | 1,836.80 - 1,836.80 |
| Zydus Lifesciences Ltd. | 1,04,265.97 | 1,036.20 | 835.50 - 835.50 |
| Mankind Pharma Ltd. | 1,03,844.60 | 2,506.70 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Akums Drugs and Pharmaceuticals inform about update on disruption in operations
Akums Drugs and Pharmaceuticals informs about disruption in operations
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January, 2026, Akums Drugs and Pharmaceuticals has informed that certain manufacturing sites at Haridwar have been impacted due to labour unrest at SIDCUL industrial area in Haridwar on 14th May, 2026. The unrest has resulted in temporarily disruption of operations and active measures are being taken to normalize the operations. Further updates and assessment of the impact will be informed in due course. Management and the local authorities are in discussions with the workers to resolve the issue quickly & amicably.
The above information is a part of company’s filings submitted to BSE.
Akums Drugs and Pharmaceuticals informs about press release
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals has informed that it enclosed a copy of press release titled, ‘Akums reports Q4 FY26 and full year FY26 results with healthy top line and strong EBITDA growth; Board recommends dividend’.
The above information is a part of company’s filings submitted to BSE.
Akums Drugs and Pharmaceuticals informs about certificate
Akums Drugs and Pharmaceuticals has informed that it enclosed a copy of the Certificate received from MUFG Intime India, the Registrar & Share Transfer Agent (RTA) of the Company, confirming the compliance of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March, 2026.
The above information is a part of company’s filings submitted to BSE.
Lenskart Solutions informs about outcome of board meeting
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Akums Drugs & Pharmaceuticals Ltd. is ₹521.35 as of 2026-05-21.
The market capitalisation of Akums Drugs & Pharmaceuticals Ltd. is ₹8,201.80 as of 2026-05-21.
The 1-year return of Akums Drugs & Pharmaceuticals Ltd. is 0.00% as of 2026-05-21.
The P/E ratio of Akums Drugs & Pharmaceuticals Ltd. is 21.49 as of 2026-05-21.
The 52-week high and low of Akums Drugs & Pharmaceuticals Ltd. are ₹622.95 and ₹409.30, respectively, as of 2026-05-21.
People Also Ask
Akums Drugs & Pharmaceuticals Limited was established in 2004 by brothers Sanjeev Jain and Sandeep Jain. They serve as the co‑founders, promoters, and managing directors, leading the company’s operations as an India‑based contract development and manufacturing organisation (CDMO) in the pharmaceutical sector.
Akums Drugs and Pharmaceuticals Ltd developed as a pharmaceutical contract manufacturing company supporting medicine production, healthcare products, and formulation development for domestic and international markets. The company began operations with a single manufacturing facility in Haridwar. Over time, it expanded into a large-scale pharmaceutical manufacturer producing tablets, capsules, and injectable formulations, and later transitioned into a publicly listed company in August 2024.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
